Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

NCT07424430 · Not yet recruiting

Last updated 2026-05-28

This study looked at how the medication semaglutide affects blood sugar, heart, and kidney health over three years in adults with type 2 diabetes or obesity.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 400 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-03 · est. completion 2026-05

What this study is testing ClinicalTrials.gov NCT07424430 ↗

Description as written by the study sponsor.

The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.

Treatments tested

Semaglutide (SEMA) Drug

participants who initiate semaglutide

Main thing measured	Change in HbA1c- 3 Years
Sponsor	LMC Diabetes & Endocrinology Ltd.
Conditions studied	Diabetes (DM), Type 2 Diabetes, Obesity (Disorder)
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07424430 ↗